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Multiple primary tumors (MPTs) affect a substantial proportion of cancer survivors and can result from various causes, including in-
herited predisposition. Currently, germline genetic testing of MPT-affected individuals for variants in cancer-predisposition genes
(CPGs) is mostly targeted by tumor type. We ascertained pre-assessed MPT individuals (with at least two primary tumors by age 60 years
or at least three by 70 years) from genetics centers and performed whole-genome sequencing (WGS) on 460 individuals from 440 fam-
ilies. Despite previous negative genetic assessment and molecular investigations, pathogenic variants in moderate- and high-risk CPGs
were detected in 67/440 (15.2%) probands. WGS detected variants that would not be (or were not) detected by targeted resequencing
strategies, including low-frequency structural variants (6/440 [1.4%] probands). In most individuals with a germline variant assessed
as pathogenic or likely pathogenic (P/LP), at least one of their tumor types was characteristic of variants in the relevant CPG. However,
in 29 probands (42.2% of those with a P/LP variant), the tumor phenotype appeared discordant. The frequency of individuals with trun-
cating or splice-site CPG variants and at least one discordant tumor type was significantly higher than in a control population (c2 ¼
43.642; p % 0.0001). 2/67 (3%) probands with P/LP variants had evidence of multiple inherited neoplasia allele syndrome (MINAS)
with deleterious variants in two CPGs. Together with variant detection rates from a previous series of similarly ascertained MPT-affected
individuals, the present results suggest that first-line comprehensive CPG analysis in an MPT cohort referred to clinical genetics services
would detect a deleterious variant in about a third of individuals.Introduction
Inherited cancer-predisposition syndromes account for
a significant minority of cancer diagnoses and provide
important opportunities for high-impact clinical interven-
tion (in probands and their relatives) through preventative
strategies in unaffected individuals (e.g., surveillance
scans, prophylactic surgery, and chemoprevention) and
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although individual CPGs are usually associated with spe-
cific tumor types.1
Traditionally, genetic testing for inherited cancer
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Figure 1. Study Design
Abbreviations are as follows: SV, structural variant; SNV, single-nucleotide variant; SO, Sequence Ontology; HGMD, Human Gene Mu-
tation Database; ACMG, American College of Medical Genetics; and IGV, Integrated Genomics Viewer.cost-effective analysis of large numbers of candidate genes.
To date, the major factors prompting investigation for
germline CPG variants have been family history and fea-
tures of specific familial cancer syndromes. In addition,
early age at cancer diagnosis and the occurrence ofmultiple
primary tumors (MPTs) in the same individual are well
recognized indicators of genetic susceptibility.2,3 MPTs
occur at appreciable frequency and are becoming more
common with aging populations and increasing cancer
survivorship.4 Aside from genetic factors, non-genetic
causes of MPT include environmental exposures relevant
tomultiple tumor types and carcinogenic cancer treatment.
Clinical NGS assays for possible inherited cancer predis-
position generally take the formof single-geneormultigene
panels of CPGs, but genome-wide analysis through whole-
exome sequencing (WES) or whole-genome sequencing
(WGS) is also possible. Although more expensive than
WES, WGS should provide the most comprehensive anal-
ysis because it (1) can effectively interrogate all coding
andnon-coding areas of the genome, (2) providesmoreuni-
form read coverage than WES, particularly in areas where4 The American Journal of Human Genetics 103, 3–18, July 5, 2018target enrichment and capture are difficult,5,6 and (3) is
able to detect a wide range of structural variations, such as
deletions, translocations, and inversions.7 However, WGS
is still in its infancy as a clinical diagnostic tool, and few
assessments of its application in hereditary cancer have
appeared in the literature. In this study, we applied WGS
to a large heterogeneous pre-assessedMPTcohort (460 indi-
viduals from 440 families) to investigate the potential role
of comprehensive CPG analysis in this group.Material and Methods
The study design is summarized in Figure 1.
Participants
460 participants from 440 families were recruited through clinical
genetics services in the UK (442 individuals), Greece (nine individ-
uals), Hong Kong (three individuals), the US (three individuals),
Israel (two individuals), and Ireland (one individual). In each
family, there was a clinical suspicion of a cancer-predisposition
syndrome, but routine genetic assessment and testing had not
Table 1. Gene List Used for Analysis (n ¼ 83)
AIP (MIM: 605555) EGFR (MIM: 131550)a NF1 (MIM: 613113) SDHB (MIM: 185470)
ALK (MIM: 105590)a EPCAM (MIM: 185535) NF2 (MIM: 607379) SDHC (MIM: 602413)
APC (MIM: 611731) ERCC2 (MIM: 126340)b NTHL1 (MIM: 602656)b SDHD (MIM: 602690)
ATM (MIM: 607585) ERCC3 (MIM: 133510)b PALB2 (MIM: 610355) SERPINA1 (MIM: 107400)b
AXIN2 (MIM: 604025) ERCC4 (MIM: 133520)b PDGFRA (MIM: 173490)a SMAD4 (MIM: 600993)
BAP1 (MIM: 603089) ERCC5 (MIM: 133530)b PHOX2B (MIM: 603851) SMARCA4 (MIM: 603254)
BMPR1A (MIM: 601299) EXT1 (MIM: 608177) PMS2 (MIM: 600259) SMARCB1 (MIM: 601607)
BRCA1 (MIM: 113705) EXT2 (MIM: 608210) POLD1 (MIM: 174761) SMARCE1 (MIM: 603111)
BRCA2 (MIM: 600185) FH (MIM: 136850) POLE (MIM: 174762) SRY (MIM: 480000)
BRIP1 (MIM: 605882) FLCN (MIM: 607273) POLH (MIM: 603968)b STK11 (MIM: 602216)
CDC73 (MIM: 607393) GATA2 (MIM: 137295) PRKAR1A (MIM: 188830) SUFU (MIM: 607035)
CDH1 (MIM: 192090) HFE (MIM: 613609)b PTCH1 (MIM: 601309) TGFBR1 (MIM: 190181)
CDK4 (MIM:123829)a HNF1A (MIM: 142410) PTEN (MIM: 601728) TMEM127 (MIM: 613403)
CDKN1B (MIM: 600778) KIT (MIM: 164920)a RAD51C (MIM: 602774) TP53 (MIM: 191170)
CDKN2A (MIM: 600160) MAX (MIM: 154950) RAD51D (MIM: 602954) TSC1 (MIM: 605284)
CDKN2B (MIM: 600431) MEN1 (MIM: 613733) RB1 (MIM: 614041) TSC2 (MIM: 191092)
CEBPA (MIM: 116897) MET (MIM: 164860)a RET (MIM: 164761)a VHL (MIM: 608537)
CHEK2 (MIM: 604373) MLH1 (MIM: 120436) RHBDF2 (MIM: 614404)a WT1 (MIM: 607102)
CYLD (MIM: 605018) MSH2 (MIM: 609309) RUNX1 (MIM: 151385) XPA (MIM: 611153)b
DDB2 (MIM: 600811) MSH6 (MIM: 600678) SDHA (MIM: 600857) XPC (MIM: 613208)b
DICER1 (MIM: 606241) MUTYH (MIM: 604933)b SDHAF2 (MIM: 613019)
aConsidered to be proto-oncogenes.
bConsidered to be associated with tumor predisposition in the homozygous or compound-heterozygous state only.identified a germline molecular genetic diagnosis at the time of
recruitment. 435 individuals had developed MPTs (defined here
as at least two primaries by age 60 years or at least three by 70
years), and 25 had developed a single primary tumor and had a
first-degree relative with MPTs. Tumors in the same tissue type
and organ were considered separate primary tumors if, in the
case of paired organs, they occurred bilaterally or if the medical re-
cord clearly denoted them as distinct. International Agency for
Research on Cancer criteria for defining separate primaries were
also used.8 Tumor diagnoses in the series were labeled according
to site and cell of origin (Table S1).
All participants gave written informed consent to participate in
the NIHR BioResource Rare Diseases, Molecular Pathology of
Human Genetic Disease (HumGenDis), and/or Investigating
Hereditary Cancer Predisposition (IHCAP) studies. The NIHR
BioResource projects were approved by research ethics committees
in the UK and appropriate ethics authorities in non-UK
enrollment centers. Ethical approval for HumGenDis and IHCAP
was given by the South Birmingham and East of England
Cambridgeshire and Hertfordshire research ethics committees,
respectively.WGS and Panel Sequencing
WGS was performed on samples from study participants as part of
the NIHR BioResource Rare Diseases study.5 Blood DNA samples
were fragmented (mean size 450 bp) with the Covaris LE220 kitTand further processed with an Illumina TruSeq DNA PCR-Free
Library Prep Kit. Libraries were sequenced with an Illumina HiSeq
2500 sequencer with one library per two lanes. FASTQ files were
generated by HiSeq Analysis Software v.2.0 (Illumina). Alignment
(GRCh37) and variant calling (including structural variants
[SVs])9,10 was performed with Isaac (Illumina).
For 411 samples, the Illumina TruSight Cancer Panel (TCP) was
also used (gene list in Table S2), and libraries were sequenced with
an Illumina MiSeq. BCL files resulting from the sequencing were
converted to FASTQ files with Illumina’s bcl2fastq. FASTQ files
were checked for coverage and other quality-control parameters
with fastqc software. FASTQ files were aligned to the UCSC
Genome Browser (hg19) with the Burrows-Wheeler Aligner
(BWA-MEM) with default parameters and SAMtools for the gener-
ation of a binary compressed sequence alignment map (BAM)
files.11,12 Variants were called from BAM files with the Genome
Analysis Toolkit Unified Genotyper algorithm.13,14 All data were
annotated with Variant Effect Predictor (VEP) v.87 on the basis
of canonical transcripts.15
SNV and Indel Identification and Assessment
Variants were extracted from VCF files if they were within a gene
specified in a comprehensive list of 83 CPGs (Table 1) and had a
predicted Sequence Ontology (SO) consequence indicating a dele-
terious effect on protein function. The gene list used for analysis
was initially composed of all genes listed in a 2014 review of
CPGs1 (n ¼ 114; gene list in Table S3) and/or those sequencedhe American Journal of Human Genetics 103, 3–18, July 5, 2018 5
by the Illumina TCP (n ¼ 94). Two additional more recently
described CPGs, namely NTHL1 (MIM: 602656)16 and CDKN2B
(MIM: 600431),17 were also included (Table S3). We subsequently
reviewed and filtered the genes to produce a list that would be
applicable to referrals to clinical cancer genetic services. Genes
were included if deleterious variants affecting them were associ-
ated with adult-onset tumors and if neoplastic lesions were likely
to be a primary presenting feature. For example, SOS1 was not
included because although Noonan syndrome is associated with
increased neoplasia risk, other features of the condition are likely
to prompt initial referral.
In order to identify clinically relevant variants, we subjected the
resulting data to a range of filters (Figure S1). First, variants were
removed if they failed to satisfy the quality criteria of a genotype
quality (GQ)R 30 (a Phred-scaled probability that the called geno-
type is incorrect), read depth (DP)R 10 (at least ten reads covering
the variant base[s]), variant allele fraction (VAF) R 33%, and filter
PASS (quality criteria applied by the Isaac variant caller in the
NIHR BioResource Rare Disease Project). Second, variants were
excluded if they had an allele frequency above 0.01 in either the
ExomeAggregationConsortium (ExAC) Browser18 (all populations)
or the 1000 Genomes Project19 (all populations). Third, variants
were retained for further review if the predicted consequence was
among a list of SO terms indicating protein truncation, if there
was evidence of pathogenicity in ClinVar20 (at least two-star evi-
dence of pathogenic or likely pathogenic [P/LP] effect correspond-
ing to multiple submissions with no conflicts as to the assertion
of clinical significance), or if the variant was assigned a disease
mutation (DM) status in the Human Gene Mutation Database
(HGMD).21 In order to consider a subset of non-truncating variants
that are predicted to be pathogenic by in silico tools but do not
appear in public databases, we also retained variants exceeding a
Phred-scaled CADD22 score threshold of 34 for further review.
CADD was selected for this purpose given that it incorporates a
range of tools and consequently a number of lines of evidence.
The threshold was chosen as themedian of scores assigned to other
variants (affecting any gene) deemed pathogenic according to the
criteria described below. Therefore, as a second variant filtering pro-
cess, variants were identified for retention solely on the basis of
CADD scores after variants retained for other reasons were assessed.
In the strategy described above, significant variants that are
located in non-coding regions, such as introns, and affect genes in
the gene list would not be extracted from the original VCF files
because their SO consequence would not be in said list. Therefore,
we usedClinVar to compile a list of known pathogenic variants fall-
ing outside of exons or splice sites and filtered VCFs on the basis of
their genomic positions in a separate interrogation. Variants were
incorporated in the list if they occurred in or near a gene in the
list,were classified as near gene, non-codingRNAor untranslated re-
gion, and had at least two-star evidence of a P/LP effect. This process
produced only three knownpathogenic variants to search for in the
WGS data. Distant non-coding variants affecting gene function
(e.g., enhancers) were not considered in the current study.
Retained variants were subsequently excluded if their putative
pathogenicity could be refuted by one of the following criteria:
(1) a predicted protein-truncating variant for which there was at
least two-star evidence of a benign or uncertain effect in ClinVar;
(2) a predicted protein-truncating variant in a proto-oncogene in a
list compiled on the basis of a literature review1 (constitutional
cancer-predisposing variants in proto-oncogenes are associated
with gain-of-function variants, so truncation of the protein
product is unlikely to increase tumor risk), (3) a predicted pro-6 The American Journal of Human Genetics 103, 3–18, July 5, 2018tein-truncating variant affecting <5% of the canonical transcript
(according to the LOFTEE VEP plugin), (4) a variant affecting a
gene associated with only recessive tumor predisposition (as
defined by a literature review1,16,23) unless an individual appeared
to harbor two filtered variants in the same gene, and (5) a variant
with HGMD DM status or that exceeded the CADD score
threshold and had at least two-star evidence of a benign or
uncertain clinical effect or one-star evidence if there were multiple
submissions without a P/LP assertion.
We used the Integrated Genomics Viewer (IGV)24 to review var-
iants that had passed filters to check for issues such as adjacent
variants affecting the predicted consequence or variants being
located at the end of sequencing reads. Pathogenicity was then as-
sessed according to the American College of Medical Genetics
(ACMG) criteria (Table S4),25 which provide a framework for
compiling multiple weighted lines of evidence. Additionally, for
each variant, it was noted whether the corresponding individual
had previously been diagnosed with a tumor typically associated
with pathogenic variants in that gene (according to Rahman,1
the Familial Cancer Database,23 or the original paper reporting
the gene as a CPG). Validation of P/LP variants was carried out
with data from the TCP or Sanger sequencing according to stan-
dard protocols if TCP data were unavailable. Primer sequences
are available on request.SV Identification and Assessment
Structural variant (SV) calls that were predicted to affect a gene on
thegene list (n¼83)werefilteredandassessedaccording to thequal-
ity of the call, rarity of the variant, and biological plausibility of tu-
mor predisposition caused by the variant (Figure S2). We initially
filtered SVs called by Canvas and/or Manta to retain those that
were predicted to affect at least one exon, occurred at a frequency
of less than 1% across all NIHR BioResource Rare Disease samples
(n ¼ 9,110), and fulfilled minimum quality criteria (GQ R 30 for
Manta, QUALR 30 for Canvas). Remaining variants were regarded
as potentially pathogenic if they affected a gene associated with tu-
mor predisposition in the heterozygous state (unless there was evi-
dence of homozygosity or compound heterozygosity) and fell into
one of the following categories: (1) copy-number loss of coding re-
gions of a tumor-suppressor gene, (2) copy-number gain of coding
regions of a proto-oncogene, and (3) any SV type with a predicted
breakpointdisrupting the gene. Subsequently, theseSVcallswere re-
viewed with IGV and excluded if they occurred in a copy-number
variationmap of the human genome26 (hg19 stringent). The occur-
rence of tumors associated with disruption of particular genes in in-
dividuals harboring suspected SVswas noted in the samemanner as
for single-nucleotide variants (SNVs) and indels. BAM files corre-
sponding to all suspected deleterious calls were reviewed in IGV.
All SVs were confirmed with Sanger sequencing according to stan-
dardprotocols. Inversions, translocations, and tandemduplications
were confirmed by sequencing across breakpoints, whereas dele-
tions were confirmed by fragment size resulting from long-range
PCR if sequencing across the breakpointwas not possible. Primer se-
quences are available on request.Comparison of MPT Series with Other Datasets
To consider how the tumor combinations in our series differed
from those in the general population, we compared combination
frequencies in our MPT data with a previously analyzed dataset
from the East Anglia Cancer Registry (2009–2014; population
size 5.5 million). Registry data recorded individuals with two
Table 2. Most Frequent Tumors and Tumor Combinations in the
Series
Tumor Category Count Percentage (%)
>5% Total (n ¼ 1,143)
Breast 281 24.6
Colorectal 113 9.9
Kidney 83 7.3
NMSC 67 5.9
Ovary 58 5.1
>1% Total (n ¼ 883)
Breast-colorectal 51 5.8
Breast-NMSC 35 4.0
Breast-ovary 34 3.9
Breast-endometrium 33 3.7
Breast-hem lymphoid 26 2.9
Breast-melanoma 24 2.7
Breast-thyroid 23 2.6
Endometrium-ovary 19 2.2
Breast-kidney 18 2.0
Colorectal-NMSC 14 1.6
Breast-lung 12 1.4
NMSC-hem lymphoid 11 1.2
Breast-soft tissue sarcoma 10 1.1
Colorectal-endometrium 9 1.0
Kidney-pituitary 9 1.0
Kidney-thyroid 9 1.0
Melanoma-NMSC 9 1.0
The following abbreviations are used: hem lymphoid, hematological
lymphoid; and NMSC, non-melanoma skin cancer (including basal cell carci-
noma and squamous cell carcinoma).cancer (or central nervous system [CNS] tumor) diagnoses before
the age of 60 years and only included tumors occurring before
that age. Consequently, only combinations in MPT data of two
malignant (or CNS) tumors occurring before 60 years of age were
considered for this comparison.
To compare detection rates of loss-of-function variants in our
cohort with a large-scale WGS dataset unselected for neoplastic
phenotypes, we interrogated gnomAD18 (data downloaded in
February 2018) for variants occurring in the same set of 83 genes.
Only truncating or splice-site variants were considered for compar-
ison purposes because these are less likely to be false positives and
made up 52/63 (82.5%) (see Results) of the P/LP variants in our
cohort. Variants extracted from gnomAD were filtered and as-
sessed in the same manner as those occurring in the MPT cohort.
The frequency of variants assessed as P/LP was also calculated for
males and females, and the sex distribution of individuals in the
gnomAD dataset (55.3% male and 44.6% female) was estimated
with mean allele count across all positions in the gnomAD VCF
file of chromosomes 1–22. In order to estimate gnomAD P/LP
variant frequency as though the sex distribution was equivalent
to that in the MPT series (23% male and 77% female), we appliedTthe sex-specific frequency to the estimated total number of
gnomAD females (n ¼ 6,929) and a reduced number of males
(n ¼ 2,064) that would achieve the desired proportion. We then
summed the respective allele-frequency estimates to provide a
figure for comparison with the MPT series.Calculation of Coverage
For BAM files from WGS and TCP data, coverage statistics for re-
gions of interest were generated with SAMtools depth.12 A BED
file compiled with Ensembl BioMart27 to represent translated
exonic regions and splice sites of genes in the gene list was utilized
for this purpose.Statistical Analysis
All statistical tests were performed with R v.3.4.3.28 Pearson’s c2
tests and Student’s t tests were performed with the chisq.test and
t.test functions, respectively.Results
Clinical Characteristics and MPT Combinations
460 individuals (106 [23%] males and 354 [77%] females)
in 440 families had been diagnosed with 1,143 primary
tumors distributed among 87 categories according to site
and cell of origin. The most frequent tumor types are illus-
trated in Table 2 (comprehensive lists are provided in
Tables S1 and S5). Representing 24.6% of the total, breast
cancer was the most frequent tumor, and colorectal cancer
was the second (9.9%). Prior genetic testing is described in
Table S6, and reasons for non-detection of the relevant
variant are illustrated in Figure 2.
The occurrence of any two discordant primary tumors in
the same individual was considered a tumor combination,
and a total of 883 combinations and 327 combination types
wereobserved (individualswith threeormorediscordant tu-
mors had multiple combinations). 206 (63%) combination
types occurred once, and 53 (16.2%) occurred twice. The
68 (20.8%) combination typesoccurring threeormore times
are illustrated in Figure 3. The most frequent combination
type was breast and colorectal cancer, which represented
5.8%of the total combinations. All combination typesmak-
ing upR1% of the total are shown in Table 2.
To compare the distributions of tumor combinations in
our MPT study cohort with a population-based dataset,
we compared 313 MPT cohort individuals comprising
523 combinations with 471 individuals comprising
574 combinations in the East Anglia Cancer Registry
data (Table S7). There was a significant difference (c2
p value < 0.05) in the frequency of tumor combinations
in 6/12 combination types that individually repre-
sented >1% of the total MPT cohort. Breast cancer in com-
bination with ovarian, thyroid, lymphoid hematological,
or kidney cancer was overrepresented in the MPT cohort,
whereas breast cancer in combination with non-mela-
noma skin was underrepresented.
Information regarding previous genetic testing was
available for 405/440 (92%) probands. No molecularhe American Journal of Human Genetics 103, 3–18, July 5, 2018 7
Figure 2. Molecular Investigations Initiated by Clinical Services with Inferred Reasons for Non-detection of Variantsinvestigations had been performed in 91 (20.7%). 159
(36.1%) had undergone BRCA1 and BRCA2 testing, 87
(19.8%) had been assessed for Lynch syndrome (where mi-
crosatellite instability [MSI] and/or immunohistochem-
istry [IHC] analysis is considered an assessment), and 159
(20.7%) had had another germline genetic test. The
mean number of genes analyzed (where MSI or IHC is
considered an analysis of four Lynch syndrome genes)
was four. Samples from 79 (18%) probands had undergone
sequencing with a multi-gene panel assay, and the mean
number of genes analyzed with these assays was 13.8.
Genetic Findings
SNVs and Indels
Variant filters applied to annotated VCF files produced 89
unique variants in 119 individuals for further ACMG-
guideline-based assessment. Of these, 22 (42 occurrences)
could be classified as pathogenic, 23 (24 occurrences) could
be classified as likely pathogenic, 24 (27 occurrences) could
be classified as a variant of uncertain significance (VUS),
and 20 (26 occurrences) could be classified as likely benign.
Six occurrences of P/LP variants occurred in two members8 The American Journal of Human Genetics 103, 3–18, July 5, 2018of the same family, and only three of these contributed to
the detection rates quoted below. No pathogenic non-cod-
ing variants were identified.
Overall, 63 variants in 17 genes in 61 (13.9%) probands
were assessed as P/LP (summary in Table 3; full descrip-
tion with phenotype and previous testing in Table S6).
Most were nonsense or frameshift variants. Individuals
with variants in moderate-risk CPGs CHEK2 (MIM:
604373; n ¼ 14) and ATM (MIM: 607585; n ¼ 10)
were the most frequent; one homozygote was detected
for CHEK2: c.1100delC (p.Thr367Metfs) (Ensembl:
ENST00000328354; GenBank: NM_007194.3]; anno-
tated in our data as c.1229delC [p.Thr410fs] [Ensembl:
ENST00000382580; GenBank: NM_001005735.1]). Indi-
viduals with variants in BRCA2 (MIM: 600185; n ¼ 6),
PALB2 (MIM: 610355; n ¼ 6), FH (MIM: 136850; n ¼ 5),
NF1 (MIM: 613113; n ¼ 4), NTHL1 (MIM: 602656; homo-
zygous, n ¼ 3), MAX (MIM: 154950; n ¼ 2), PTEN
(MIM: 601728; n ¼ 2), SDHB (MIM: 185470; n ¼ 2),
BMPR1A (MIM: 601299; n ¼ 1), BRCA1 (MIM: 113705;
n ¼ 1), CDKN1B (MIM: 600778; n ¼ 1), EXT2 (MIM:
608210; n ¼ 1), MLH1 (MIM: 120436; n ¼ 1), MSH2
Figure 3. Most Frequent Tumor Combi-
nation Types
Combination types occurring fewer than
three times are not included. Abbreviations
are as follows: pheo, pheochromocytoma;
GI NET, gastrointestinal neuroendocrine
tumor; hem myeloid, hematological
myeloid; PNET, pancreatic neuroendocrine
tumor; hem lymphoid, hematological
lymphoid; and NMSC, non-melanoma
skin cancer (including basal cell carcinoma
and squamous cell carcinoma).(MIM: 609309; n ¼ 1), and PMS2 (MIM: 600259; n ¼ 1)
were also noted.
The 61 P/LP SNV and indels detected by WGS were
confirmed by a second analysis (TCP for 51 variants and
Sanger sequencing for ten variants).
Pre-testing information was available for 57/63 P/LP var-
iants, 41/57 (71.9%) of which occurred in an individual
who had at least one previous genetic test and 7/57
(12.3%) of which were eventually detected by clinical ser-
vices. No P/LP variants were observed in genes that had
previously been tested in a sample from the relevant indi-
vidual by diagnostic services (Figure 2). The mean number
of genes tested in those with a P/LP variant was 5.3, which
was not significantly different from that in probands
without such variants detected (Student’s t test p ¼ 0.396).
Of the 61 probands identified with a P/LP variant, 36
(59%; 8.2% of all probands) had previously been diag-
nosed with a tumor typically associated with the relevant
CPG. A further eight (1.8%) probands were found to har-
bor a VUS and had been diagnosed with an associated
tumor.
Two probands harbored two P/LP variants in multiple
CPGs. One individual with colorectal adenocarcinoma at
age 50 years and breast cancer at 57 years carried a
PMS2 frameshift variant (c.741742insTGAAG [p.Pro247_
Ser248fs] [Ensembl: ENST00000265849; GenBank:
NM_000535.6]) and a BMPR1A nonsense variantThe American Journal of(c.730C>T [p.Arg244*] [Ensembl:
ENST00000372037; GenBank: NM_
004329.2]). Immunohistochemistry
of the bowel tumor showed loss of
PMS2; MSI was also demonstrated,
leading to diagnostic sequencing of
PMS2, although there was no family
history of neoplasia other than an
ovarian cancer in a second-degree
relative after age 70 years. The pro-
band had previously undergone
surveillance colonoscopy for inflam-
matory bowel disease, resulting in
the identification of a number of
polyps; however, there was no evi-
dence from histology reports that
these were juvenile polyps. Addition-ally, an individual with bilateral pheochromocytoma at
ages 16 and 35 years and no reported family history of
neoplasia was identified with variants in FH (c.521C>G
[p.Pro174Arg] [Ensembl: ENST00000366560; GenBank:
NM_000143.3]) and MAX (c.1A>G [p.Met1Val] [Ensembl:
ENST00000358664; GenBank: NM_002382.4]).29 The
latter variant is predicted to abolish the MAX initiation
codon, and previous analysis of tumor tissue from an indi-
vidual carrying it demonstrated loss of the wild-type allele
and a lack of full-length MAX protein product.30
Coverage and Comparison with Panel
Mean depth in WGS data of coding bases in the 83 genes
analyzed was 353 (SD ¼ 7.5), and 100% were covered
atR103. Coverage was also considered for 68 of the genes
also sequenced by the TCP. In WGS data, 100% of target
bases were covered at R103, and the mean depth was
35.3 (SD ¼ 7.4). Coverage analysis pertaining to those
68 genes from the 411 (89.3%) participants also undergo-
ing sequencing with the TCP showed 99.1% target bases
atR103 and a mean depth of 807.3 (SD ¼ 793.2).
A comparison of the variant detection was performed on
the basis of the 105 ACMG-assessed SNVs and indels
that were detected by WGS and were within a gene
sequenced by the TCP. 99/105 variants were called from
TCP data with quality indicators sufficient to pass filters
used for the WGS data. Five undetected variants—
including one P/LP PMS2 variant (c.741742insTGAAGHuman Genetics 103, 3–18, July 5, 2018 9
Table 3. Summary of Filtered SNVs and Indels Deemed Pathogenic or Likely Pathogenic by ACMG Assessment
Gene RefSeq mRNA ID
No. of
Occurrences
No. of Individuals
with Associated
Tumor Variant Description Consequence
ATM GenBank: NM_000051 1 1 c.193C>T (p.Gln65*) stop gain
ATM GenBank: NM_000051 1 1 c.5623C>T (p.Arg1875*) stop gain
ATM GenBank: NM_000051 1 0 c.6583þ1G>A splice site (donor)
ATM GenBank: NM_000051 1 0 c.6866-6867insT (p.Ser2289Serfs) frameshift
ATM GenBank: NM_000051 1 1 c.748C>T (p.Arg250*) stop gain
ATM GenBank: NM_000051 1 1 c.8147T>C (p.Val2716Ala) missense
ATM GenBank: NM_000051 1 0 c.8405delA (p.Gln2802fs) frameshift
ATM GenBank: NM_000051 1 0 c.5821G>C (p.Val1941Leu) missense
ATM GenBank: NM_000051 1 0 c.8122G>A (p.Asp2708Asn) missense
ATM GenBank: NM_000051 1 1 c.7775C>G (p.Ser2592Cys) missense
BMPR1Aa GenBank: NM_004329 1 1 c.730C>T (p.Arg244*) stop gain
BRCA1 GenBank: NM_007300 1 1 c.19611962insA (p.Lys654fs) frameshift
BRCA2 GenBank: NM_000059 1 0 c.4525C>T (p.Gln1509*) stop gain
BRCA2 GenBank: NM_000059 1 1 c.5682C>G (p.Tyr1894*) stop gain
BRCA2 GenBank: NM_000059 1 0 c.62756276delTT (p.Leu2092fs) frameshift
BRCA2 GenBank: NM_000059 1 1 c.64026406delTAACT (p.Asn2135Leufs) frameshift
BRCA2 GenBank: NM_000059 1 0 c.65356536insA (p.Val2179fs) frameshift
BRCA2 GenBank: NM_000059 1 1 c.18051806insA (p.Gly602fs) frameshift
CDKN1B GenBank: NM_004064 1 0 c.148149delAG (p.Arg50fs) frameshift
CHEK2 GenBank: NM_001005735 3 1 c.1392delT (p.Leu464fs) frameshift
CHEK2 GenBank: NM_001005735 10 6 c.1229delC (p.Thr410fs) frameshift
CHEK2 GenBank: NM_001005735 1 1 c.1051þ1C>T splice site (donor)
CHEK2 GenBank: NM_001005735 1 0 c.784delG (p.Glu262fs) frameshift
CHEK2 GenBank: NM_001005735 1 1 c.562C>T (p.Arg188Trp) missense
EXT2 GenBank: NM_000401 1 0 c.613C>T (p.Gln205*) stop gain
FH GenBank: NM_000143 3 0 c.14331434insAAA
(p.Lys477_Asn478insLys)
in-frame insertion
FH GenBank: NM_000143 1 1 c.320A>C (p.Asn107Thr) missense
FHb GenBank: NM_000143 1 0 c.521C>G (p.Pro174Arg) missense
MAX GenBank: NM_002382 1 1 c.289C>T (p.Gln97*) stop gain
MAXb GenBank: NM_002382 1 1 c.1A>G (p.Met1Val) start loss
MLH1 GenBank: NM_000249,
NM_001258273
1 1 c.18841G>A splice site (acceptor)
MSH2 GenBank: NM_000251 1 0 c.14521455insAATG (p.Leu484-Met485fs) frameshift
NF1 GenBank: NM_001042492 1 1 c.15411542delAG (p.Gln514fs) frameshift
NF1 GenBank: NM_001042492 1 1 c.4620delA (p.Ala1540fs) frameshift
NF1 GenBank: NM_001042492 1 1 c.5831delT (p.Leu1944fs) frameshift
NF1 GenBank: NM_001042492 1 1 c.7768-7769insA (p.His2590fs) frameshift
NTHL1c GenBank: NM_002528 3 3 c.268C>T (p.Gln90*) stop gain
PALB2 GenBank: NM_024675 4 3 c.3113G>A (p.Trp1038*) stop gain
PALB2 GenBank: NM_024675 1 1 c.3116delA (p.Asn1039fs) frameshift
(Continued on next page)
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Table 3. Continued
Gene RefSeq mRNA ID
No. of
Occurrences
No. of Individuals
with Associated
Tumor Variant Description Consequence
PALB2 GenBank: NM_024675 1 1 c.62T>G (p.Leu21*) stop gain
PMS2a GenBank: NM_000535 1 1 c.741742insTGAAG (p.Pro247_S248fs) frameshift
PTEN GenBank: NM_000314 1 1 c.1003C>T (p.Arg335*) stop gain
PTEN GenBank: NM_000314 1 1 c.697C>T (p.Arg233*) stop gain
SDHB GenBank: NM_003000 1 1 c.223þ1C>A splice site (donor)
SDHB GenBank: NM_003000 1 1 c.689G>A (p.Arg230His) missense
This list incorporates one individual per family. See Table S6 for more comprehensive description.
aOccurring in the same individual.
bOccurring in the same individual.
cHomozygous.[p.Pro247_Ser248fs] [Ensembl: ENST00000265849; Gen-
Bank: NM_000535.6]), where 58/202 (20.6%) reads con-
tained the insertion—were indels for which IGV review
showed a VAF below the threshold for filtering. One unde-
tected variant in TMEM127 (MIM: 613403) (c.665C>T
[p.Ala222Val] [Ensembl: ENST00000258439; GenBank:
NM_017849.3]) was covered by only two reads.
The filtering and assessment process applied to WGS
data was also used for variants called from TCP data gener-
ated from the same 411 individuals. 108/110 TCP variants
that passed filters and went forward for ACMG assessment
were also called fromWGS data, meaning that two variants
(assessed as pathogenic) were not detected by WGS. This
was because the VAF was marginally below the filtering
threshold of 33% for ATM (c.2426C>A [p.Ser809*]
[Ensembl: ENST00000278616; GenBank: NM_000051])
(7/22 [32%] reads) and MAX (c.97C>T [p.Arg33*]
[Ensembl: ENST00000358664; GenBank: NM_002382])
(9/29 [31%] reads).
Comparison of MPT WGS SNV and Indel Detection with
gnomAD Dataset
In our dataset, 52 truncating or splice-site variants
were observed in 440 MPT probands, whereas 298
were observed in 8,992 gnomAD genomes; the latter
is based on observed variant frequency estimates
adjusted to reflect sex distribution of the MPT series
(13.6% for the MPT dataset versus 3.3% for the gnomAD
dataset; c2 ¼ 84.903, p ¼ < 0.0001). 41 truncating
or splice-site CPG variants occurred in a proband
with at least one tumor type uncharacteristic of the
relevant CPG, and the frequency of such variants in
these individuals was also compared with that in
gnomAD. This was significantly higher in the MPT pro-
bands with uncharacteristic tumors than in gnomAD
(41/440 [9.3%] versus 298/8,992 [3.3%]; c2 ¼ 43.642;
p % 0.0001).
SVs
SV analysis revealed six potentially pathogenic variants in
440 (1.4%) probands (Table 4), two of whom had previ-
ously been diagnosed with tumors typically associatedThwith variants in the relevant gene. An additional two
had no associated tumor but a family history of such
tumors in a first-degree relative (colorectal cancer at age
56 years for the individual with a SMAD4 translocation
and renal cell carcinoma at age 69 for the individual
with the TSC1 duplication). One individual with an inver-
sion of PTEN exon 7 had been diagnosed with breast can-
cer at age 45 years and had a strong family history of this
tumor, which had occurred in her sister (age 57 years),
mother (age 57 years), and maternal cousin (age 49 years).
The proband’s sister had also been diagnosed with a
borderline ovarian mucinous tumor and nasal basal cell
carcinoma at 46 and 57 years of age, respectively, but
WGS did not detect the PTEN inversion in her sample.
Another individual had previously been investigated
with germline FH sequencing after the diagnosis of multi-
ple cutaneous leiomyomas and a family history of a first-
degree relative undergoing a hysterectomy for uterine
leiomyomas. SV analysis revealed a whole-gene deletion
of FH.
Combined Variant Detection Rate
After combining SVs passing our filters and ACMG-
assessed P/LP SNVs and indels, we observed a P/LP variant
in 67 (15.2%) probands tested. 38 probands (8.6% of total)
had such a variant and a typically associated tumor. There
was no significant difference in P/LP detection rate be-
tween probands diagnosed with a rare tumor and those
who hadn’t been (27/136 [19.8%] versus 40/304 [13.1%];
c2 ¼ 3.2628; p ¼ 0.07087). Of the 55/67 probands for
whom a family history was available, there was no cancer
diagnosis in a first-degree relative younger than 50 years
in 23 individuals (61.8%) and younger than 60 years in
34 individuals (61.8%).
Limited numbers of family members participated in
the study, preventing large-scale segregation analysis.
Of the 69 P/LP variants (including SVs) of interest de-
tected in probands, the relevant locus was sequenced in
a family member on seven occasions. The relevant
variant was detected in four of seven family members,
two of whom had been diagnosed with a typicallye American Journal of Human Genetics 103, 3–18, July 5, 2018 11
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variants).Discussion
Variant Detection Rates in an MPT Series
We previously reported a retrospective series of MPT indi-
viduals (defined as having two primary tumors before 60
years of age) referred to a UK clinical genetics service
without pre-assessment and observed that 20.7%
(44/212) were found to have a molecular diagnosis upon
routine targeted molecular genetic testing, including
BRCA1 and BRCA2 testing, mismatch-repair gene analysis,
or other single-gene testing (APC [MIM: 611731], MUTYH
[MIM: 604933], PTEN, TP53 [MIM: 191170], and RB1
[MIM: 614041]).31
In the current study, we addressed whether comprehen-
sive genetic analysis in pre-assessed individuals with MPTs
might increase the diagnostic yield over routine targeted
testing. Thus, we analyzed 460 MPT-affected individuals
who had previously undergone routine genetic assessment
and/or molecular testing (but without a molecular diag-
nosis) by usingWGS for variants in 83 CPGs and identified
a P/LP variant in 67/440 (15.2%) probands (incorporating
SNVs, indels, and SVs), including those affected by moder-
ate- and high-risk CPGs.
Because the MPT cohort reported here was mostly
ascertained from UK genetics centers (and was similar to
the previous retrospective cohort that did not have a
known genetic cause), we estimate (by assuming that
WGS would detect variants identified by routine targeted
sequencing approaches) that comprehensive genetic
analysis in a genetics-center-referred series of individuals
with MPTs (and no prior genetic testing) would detect a
P/LP variant in around a third of individuals (20.7% þ
12.1% [estimated under the assumption of a diagnostic
yield of 15.2% in the 79.3% of individuals without a
variant in routine testing] ¼ 32.8%). The estimated pro-
portion of individuals with a P/LP variant and a typical tu-
mor would be 27.5% (20.7% [all of those with variants
detected by targeted analysis had a typical tumor] þ
[79.3% 3 8.6% ¼ 6.8%]). Therefore, in individuals seen
in a genetic clinic, the presence of MPTs (two tumors
before 60 years of age or three before 70 years of age)
could be taken as an indication for considering genetic
testing.
The estimates for diagnostic yield are approximate and
would be influenced by ascertainment processes but do
suggest that a comprehensive testing for CPG variants
significantly increases the detection of P/LP variants over
the targeted testing that has been routinely employed in
most genetics centers.
Most MPT-affected individuals (38/67 [56.7%] and
38/440 [8.6%] of all pre-assessed probands tested in the
current study) with a P/LP variant had been diagnosed
with a tumor type characteristically associated with
variants in the relevant CPG, findings that have the great-
est clinical utility. In, addition, a further 8/440 (1.8%) had
a VUS and a previous diagnosis of a characteristic tumor.
Such VUSs might eventually be reclassified as LP variants
with further investigations (e.g., tumor studies or func-
tional analysis) or additional clinical information (e.g.,
segregation analysis). However, interpretation of segrega-
tion data should be cautious in cancer-predisposition
syndromes because of incomplete penetrance and a higher
probability of phenocopies. Tumor studies for loss of
heterozygosity do not provide absolute confirmation or
exclusion of pathogenicity, and together these consider-
ations reinforce the importance of data-sharing initiatives
such as ClinVar.20
Amajor influence on the number and pattern of variants
detected in a study such as this is the tumor phenotypes
occurring in the cohort, which in this case reflect both
the population incidence and the patterns of referral for
genetic assessment and investigation. Compared with
MPT-affected individuals in cancer registries, our series is
enriched with combinations such as breast-ovary (4.4%
versus 1.9%) and breast-colorectal (5.5% versus 2.8%),
most likely reflecting common cancers with a significant
hereditary component and for which genetic testing has
been routinely available for a number of years. Many of
these cancers are sex specific, most likely contributing to
the uneven sex distribution in this series. Some combina-
tion types making up >1% of MPT combinations, e.g.,
breast-thyroid (3.6% in MPT data), are not observed
frequently (<1%) in the population-based cohort used
here, which could be accounted for by referral prompted
by suspicion of germline PTEN variants.
Breast cancer accounted for almost a quarter of tumors in
our series, and most genes in which deleterious variants
were detected are breast CPGs, many of which are not
routinely tested in the UK. Pathogenic variants in ATM
and CHEK2 are associated with moderate risks,32,33 and
these genes had not been tested by the referring center
in any of the individuals with P/LP variants. Six probands
had pathogenic variants in PALB2, a gene initially thought
to confer moderate risk34 but subsequently reported
to have a penetrance somewhere between that of moder-
ate- and high-risk genes such as BRCA1 and BRCA2.35
Genes can remain uninvestigated by clinicians not only
because of uncertainty surrounding risks but also because
of recency of discovery. A number of CPGs in which vari-
ants were identified, such as MAX and FH, have been rela-
tively recently described as causing pheochromocytoma
and paraganglioma. The appearance of these variants in
this analysis most likely reflects a lack of availability of
testing at the time of consultation and subsequent referral
for inclusion in the study. Molecular genetic testing has
been available for other genes such as MLH1 and PTEN
for a greater period of time, but some individuals appeared
not to have fulfilled the clinical testing criteria applied in
the referring center. TP53 is a further well-established
CPG that is associated with diverse and multiple cancersThand has clear clinical testing criteria that are often not ful-
filled. Despite this, no pathogenic variants were detected.
Germline TP53-variant-related phenotypes (including
rare and/or early-onset cancers) are more clearly identifi-
able clinically and are less likely to appear in cohorts
such as ours without specific ascertainment for them.
Consistent with this are mutation detection rates of 4%
in individuals with earlier-onset (%30 years) breast can-
cer36 and 17% in MPT-affected individuals who were
referred for germline TP53 testing and who generally ful-
filled criteria for that investigation, had tumors character-
istic of Li Fraumeni syndrome, and had an average age at
diagnosis (of a first primary tumor) before 30 years.2
Although we report the application of WGS to an adult
MPT series, other studies have used agnostic NGS strategies
in cohorts with single-site cancer. The detection rate of
pathogenic variants in these analyses could be influenced
by the assay used, the variant filtering and assessment
applied, and the nature of the series in terms of both
phenotype and ascertainment. The application of a
76-gene panel to 1,000 cancer-affected adults referred
for germline genetic testing and ACMG-guideline-based
assessment of the resulting variants showed a 17.5%
rate,37 whereas tumor-normal sequencing of a similarly
sized series with advanced cancer from the same center
(regardless of genetic testing referral) reported an equiva-
lent figure of 12.6%.38 The genes containing the most
frequent pathogenic variants in both studies were similar
to those in the current study (BRCA1, BRCA2, CHEK2,
and ATM), but the detection rates were lower than our
estimate of around a third of newly referred MPT-affected
individuals, most likely reflecting a greater likelihood of a
germline pathogenic variant in both genetics referrals
and in MPT-affected individuals. Studies of WGS and/or
WES applied to unselected pediatric cancer series have
also shown pathogenic-variant detection rates close to
10% but a contrasting range of affected genes, suggesting
that TP53 and genes associated with embryonal tumors
play a far greater role.39–41
Atypical Tumor-Variant Associations in MPT-Affected
Individuals
In this study, we applied multi-gene testing in all affected
individuals irrespective of the tumor types diagnosed.
Strikingly, this resulted in the identification of a large
number of probands (29/67 [43.2%]) who harbored a
P/LP CPG variant but whose tumor phenotypes were
not entirely typical for the relevant CPG. This situation
has been frequently reported by other studies of exten-
sive NGS testing of cancer cohorts37,40,42 and represents
a challenge for clinicians because the relevance of the
variant to cancer risk in the consultand (including unaf-
fected family members) is less clear. Specific atypical asso-
ciations observed in this analysis were heterogeneous,
and numbers were small, but some patterns were noted;
for example, 5/16 (31.2%) carriers of CHEK2 variants
had been previously diagnosed with renal cell carcinomae American Journal of Human Genetics 103, 3–18, July 5, 2018 13
(RCC) (breast cancer occurred in 8/16 [50%]). An odds
ratio of 2.1 for RCC has previously been observed in
CHEK2-variant carriers but only in association with the
c.470T>C (p.Ile157Thr) founder variant in a Polish pop-
ulation.43 2/6 (33.3%) carriers of PALB2 variants had cuta-
neous melanoma before the age of 40 years, and 2/10
(20%) individuals with ATM variants had thyroid cancer
before that age, but an analysis of 182 melanoma families
demonstrated only one pathogenic PALB2 variant,44 and
thyroid malignancies have not been reported at increased
frequency in carriers of homozygous or heterozygous
ATM variants.1,45
One potential interpretation of these atypical tumor
phenotypes is that the tumor spectrum associated with
some CPGs is wider than currently recognized given that,
to date, testing of particular genes has been limited to
specific phenotypes. For example, although FH variants
were demonstrated to predispose to RCC in 2002, they
were shown to predispose to pheochromocytoma and
paraganglioma 12 years later.46–48 We therefore suggest
that further ‘‘agnostic’’ research testing of a compre-
hensive panel of CPGs in MPT-affected individuals
could lead to the identification of novel associations be-
tween genes and tumor phenotypes. Our observation of
a significantly higher rate of loss-of-function variants
associated with non-characteristic tumors in our cohort
than in the gnomAD dataset suggests that at least some
variants identified in individuals with atypical phenotypes
are relevant. We would, however, urge caution in automat-
ically linking a pathogenic CPG variant to the observed tu-
mor phenotype without further evidence, such as larger
studies of variant carriers or tumor studies that demon-
strate a variant’s causative effect.
Another possibility is that tumors can occur coinciden-
tally in the presence of a pathogenic constitutional CPG
variant. Variants might be considered causative in some
contexts or tissues (and would therefore be likely to
pass our filtering and assessment) but potentially not
in others. For example, an in-frame FH insertion
(c.14331434insAAA [p.Lys477_Asn478insLys] [Ensembl:
ENST00000366560; GenBank: NM_000143.3]) was identi-
fied in three individuals, none of whom had been diag-
nosed with typical hereditary leiomyoma or RCC tumors.
This variant causes recessively inherited fumarate hydra-
tase deficiency (MIM: 606812) and has been demonstrated
to disrupt enzyme activity.49 However, its significance to
cancer predisposition in the heterozygous state is less
well defined.
Unusual MPT-CPG associations can occur when an indi-
vidual harbors variants in multiple CPGs, either because
(at least) one of the variants remains unidentified through
diagnostic testing or because an interactive effect exists
between them.We have previously reviewed this phenom-
enon and described it as multiple inherited neoplasia
alleles syndrome (MINAS),50 and WGS identified two
further examples in our cohort. In the case of PMS2 and
BMPR1A variants, the former appears to be penetrant on14 The American Journal of Human Genetics 103, 3–18, July 5, 2018the basis of tumor studies, whereas the significance of
the latter is unclear. Nevertheless, the identification of
MINAS cases such as this provides clinicians the opportu-
nity to obtain further evidence. For the individual with
FH andMAX variants, it is easier to attribute the diagnosed
pheochromocytomas to the truncating MAX variant, but
evidence for the role of FH in this tumor type is accumu-
lating, and this variant could have contributed to
tumorigenesis.
Value of Germline WGS in the Analysis of MPTs
Although WGS could arguably offer the most sensitive
and comprehensive strategy for detecting germline CPG
variants, it is resource intensive in terms of sequencing,
data storage, and analytical capacity. In this study,
the conservative variant filtering and assessment and
the small number of non-coding variants that were
used for data interrogation reduced the post-sequencing
burden of variants, but small changes to these processes
would lead to significant increases with uncertain clinical
utility. The approximate cost per sample of WGS as part
of the NIHR BioResource Rare Disease project is $1,400,
consistent with figures collated by the National Human
Genome Research Institute in 2016 and higher than the
$1,000 per exome derived from that survey.51 The TCP
in our department is currently charged at around $450
per sample. Justification of the extra costs compared
with those of other NGS assays, such as panel tests or
WES, requires the demonstration that WGS can increase
the diagnostic rate over that of other approaches through
enhanced detection of coding SNVs and indels, SV iden-
tification, or analysis of non-coding regions.
In our analysis, the TCP produced a higher mean depth
but a slightly lower percentage of target bases covered
at R103 than the equivalent regions in WGS data
(99.1% versus 100%). WGS identified one TMEM127
SNV (assessed as a VUS) that wasn’t detected by the
TCP because the relevant nucleotide was covered by
only two reads. Five additional filtered variants from
the WGS data weren’t called from panel data, and one
of them was assessed as likely pathogenic. This was
because the VAF was marginally below the chosen
threshold, an issue that also accounted for the calling
of two pathogenic variants from TCP data but not from
WGS. Non-detection of lower-VAF variants could be
resolved through more sensitive bioinformatic filtering
of data from either assay. 15 genes on our list of 83
were not targeted by the panel (but no significant vari-
ants were detected in them). This illustrates the broader
scope of WGS, but our results do not suggest that WGS
offers enhanced CPG SNV or indel detection at present.
WGS identified six SVs predicted to affect a gene of inter-
est, and two of these occurred in an individual whose
personal or family history included tumors consistent
with variants in that gene. The medical record showed
no evidence that the individual with the PTEN inversion
exhibited other features of constitutional variants in this
gene, such as macrocephaly, as well as no record of an ex-
amination in a consultation where only BRCA1 and BRCA2
testing was anticipated. Although the numbers of poten-
tially pertinent SVs are small, these aberrations are unlikely
to be detected by panel or exome sequencing alone. Copy-
number variation can be identified from the analysis of
read counts in WES or panel data,52 but most diagnostic
laboratories rely on techniques such as multiplex probe
ligation assays (MLPAs) to test individual genes. If MLPA
analysis is applied to many genes, then the cost could
make WGS more economical than WES or panel-based
testing, but investigating this would require a detailed
cost-benefit analysis. Furthermore, WGS can detect inver-
sions and translocations that are not characterized by
MLPA. A note of caution, however, arises from a deletion
involving BRCA2 exons 14–16; we were made aware of
this deletion by the referring clinician, but it was not de-
tected through our analyses.
Given the limited benefits of WGS over WES and panel
analysis demonstrated in this study, a key advantage is
the ability to prospectively or retrospectively interrogate
regions that are not currently known to be clinically
relevant. This includes novel CPGs (many of the P/LP var-
iants in this analysis were detected because the gene or re-
gion was not available for testing at the time of consulta-
tion). WGS costs should therefore be considered in the
context of possible future demand for re-investigation
and the consequent resource burden required for this if
the region of interest (including non-coding regions) is
not sequenced in the first instance. Adequate systems
for prioritizing and assessing the multitude of non-coding
variants generated by WGS for clinical use do not yet
exist.53 Consequently, few clinically non-coding variants
are currently known, and we did not identify any of them
in this analysis. However, evidence of regulatory ele-
ments that influence the expression of any given gene
is accumulating,54 and high-throughput functional as-
says for studying them provide the opportunity to define
diagnostically significant variants affecting CPGs.55 If this
process were able to elucidate clinically relevant variants,
the case for WGS as a first-line investigative tool would
become more compelling.
In summary, we have demonstrated that the applica-
tion of comprehensive CPG testing to a cohort of
previously investigated MPT-affected individuals resulted
in the detection of multiple pathogenic variants with
relevance to the management of those individuals
and their relatives. The finding that comprehensive ge-
netic analysis of MPT-affected individuals can frequently
result in the identification of pathogenic CPG variants
that cannot automatically be attributed as causative for
the observed MPT clinical phenotype has important
implications both for clinical practice and for future
research into the phenotypic consequences of germline
CPG variants. Summing together variant detection rates
from a previous series of MPT-affected individuals
ascertained in a similar manner and the present resultsThsuggests that first-line application of WGS (or other
strategies for comprehensive CPG variant detection) to
a clinical-genetics-referral-based cohort of MPT-affected
individuals would detect a deleterious mutation in about
a third of individuals, a large proportion of whom would
not have a family history of cancer in a first-degree
relative.Accession Numbers
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